REGN-COV2 Antibody Cocktail
Chemical Name | casirivimab and imdevimab |
Dosage Form | Injection (intravenous; 120 mg/mL casirivimab/120 mg/mL imdevimab) |
Drug Class | Monoclonal antibodies |
System | Respiratory |
Company | Regeneron Pharmaceuticals |
Approval Year | 2020 |
Indication
- For the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID19 and/or hospitalization.